With a market share of 37,6% recorded in 2024 [1], the European pharmaceuticals sector is a solid building block of the regional economy. As research into diseases and alternative treatments continues to progress, this sector is also growing, extending from well-established everyday drugs like aspirin and insulin to advanced biopharmaceuticals and biotechnological materials. Translating such diversity into the specifics of modern supply chains is a significant challenge on the logistics front. In the European Union, about 80% of pharma products now require temperature-controlled transportation [2] – a setup that creates high demand for cold chain logistics solutions. Vaccines, insulin, and other temperature-sensitive medications are highly vulnerable to fluctuations in temperature, and even slight variations can degrade their quality and efficacy, making them ineffective or even harmful to patients. Additional pressure also comes from EU regulatory bodies. For years, pharmaceutical regulations in most countries required products to be kept within manufacturer-established guidelines only during storage. It all changed when the European Union issued guidelines on Good Distribution Practices (GDP) for medicinal products for human use, extending temperature requirements to transportation and expanding coverage to include over-the-counter drugs. [3]. (....)